Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gyre TherapeuticsGYRE +2.14%39 3-1 Month Momentum % is -9.43% as of Aug. 16, 2026. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.44 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,388 Biotechnology companies, Gyre Therapeutics ranks worse than 52.88% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-16), Gyre Therapeutics's 3-1 Month Momentum % is -9.43%.
The industry rank for Gyre Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
GYRE's 3-1 Month Momentum % is ranked worse than 52.88% of 1388
companies
in the Biotechnology industry
Industry Median: -8.025
vs GYRE: -9.43
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gyre Therapeutics 3-1 Month Momentum % Related Terms
GYRE vs OCS, RIGL, SGP: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Gyre Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a 3-1 Month Momentum % of -9.43% as of Aug. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #734 out of 1388 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Gyre Therapeutics' 3-1 Month Momentum % too high?
Gyre Therapeutics' current 3-1 Month Momentum % is -9.43%. Based on the distribution chart, Gyre Therapeutics ranks #734 out of 1388 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' 3-1 Month Momentum % compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #734 out of 1388 companies for 3-1 Month Momentum %. This places Gyre Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current 3-1 Month Momentum % is -9.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.44, compared to a current price of $6.68 — trading 29.2% below its estimated fair value. The current 3-1 Month Momentum % is -9.43%. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current 3-1 Month Momentum % is -9.43% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.68 is trading 29.2% below its estimated GF Value™ of $9.44.
GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.
Key valuation signals for GYRE:
3-1 Month Momentum %: -9.43%
GF Value™: $9.44 vs. price of $6.68 (29.2% below fair value)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
